1. A compound of formula (I):
and pharmaceutically acceptable salts thereof, and individual enantiomers and diastereomers thereof, wherein:
X and Y are selected from the group consisting of
(1) hydrogen,
(2) \u2014C1-3 alkyl,
(3) halogen, and
(4) cyano;
A is selected from the group consisting of
(1) hydrogen,
(2) \u2014C1-10 alkyl,
(3) \u2014C2-10 alkenyl, and
(4) \u2014C2-10 alkynyl,
wherein said alkyl, alkenyl or alkynyl is unsubstituted or substituted with one or more
(a) halo,
(b) \u2014C3-8 cycloalkyl,
(c) \u2014OH,
(d) \u2014CN,
(e) \u2014O\u2014C1-10 alkyl,
(f) \u2014C6-10 aryl, or
(g) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl,
and said aryl and heteroaryl groups are unsubstituted or substituted with one or more
(i) halo,
(ii) \u2014OH,
(iii) \u2014CN,
(iv) \u2014O\u2014C1-10 alkyl,
(v) \u2014C1-10 alkyl,
(vi) \u2014C2-10 alkenyl,
(vii) \u2014C2-10 alkynyl, or
(viii) \u2014C3-8 cycloalkyl;
R1 is phenylene, wherein said phenylene is unsubstituted or substituted with one or more
(a) halo,
(b) \u2014C1-10 alkyl,
(c) \u2014C2-10 alkenyl,
(d) \u2014C2-10 alkynyl,
(e) \u2014OH,
(f) \u2014CN,
(g) \u2014O\u2014C1-10 alkyl, or
(h) \u2014C3-8 cycloalkyl;
R2 is selected from the group consisting of:
(1) (R5\u2014SO2)N(R6)\u2014, wherein R5 is
(a) \u2014C1-10 alkyl,
(b) \u2014C2-10 alkenyl,
(c) \u2014C2-10 alkynyl,
(d) \u2014C3-8 cycloalkyl,
(e) \u2014C6-10 aryl, or
(f) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl,
(g) \u2014NR7R8,
wherein said alkyl, alkenyl, alkynyl, cycloalkyl, aryl and heteroaryl is unsubstituted or substituted with one or more
(i) halo,
(ii) \u2014OH,
(iii) \u2014CN,
(iv) \u2014O\u2014C1-10 alkyl,
(v) \u2014C1-10 alkyl,
(vi) \u2014C2-10 alkenyl,
(vii) \u2014C2-10 alkynyl,
(viii) \u2014C3-8 cycloalkyl,
(ix) \u2014C6-10 aryl, or
(x) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl,
and said aryl and heteroaryl is unsubstituted or substituted with one or more
(A) halo,
(B) \u2014OH,
(C) \u2014CN,
(D) \u2014O\u2014C1-10 alkyl,
(E) \u2014C3-8 cycloalkyl,
(F) \u2014C1-10 alkyl,
(G) \u2014C2-10 alkenyl, or
(H) \u2014C2-10 alkynyl;
R6 is selected from the group consisting of
(a) hydrogen,
(b) \u2014C1-10 alkyl,
(c) \u2014C2-10 alkenyl,
(d) \u2014C2-10 alkynyl,
(e) \u2014C6-10 aryl, or
(f) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl,
wherein said alkyl, alkenyl, alkynyl, aryl or heteroaryl is unsubstituted or substituted with one or more
(i) halo,
(ii) \u2014OH,
(iii) \u2014CN,
(iv) \u2014O\u2014C1-10 alkyl,
(v) \u2014C3-8 cycloalkyl,
(vi) \u2014C6-10 aryl, or
(vii) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl;
wherein said cycloalkyl, aryl or heteroaryl is unsubstituted or substituted with one or more
(A) halo,
(B) \u2014OH,
(C) \u2014CN,
(D) \u2014O\u2014C1-10 alkyl,
(E) \u2014C3-8 cycloalkyl, or
(F) \u2014C6-10 aryl,
or R5 and R6 may be linked to form a group \u2014CH2(CH2)pCH2\u2014;
(2) \u2014C6-10 aryl, wherein said aryl is unsubstituted or substituted with one or more
(i) halo,
(ii) \u2014OH,
(iii) \u2014CN,
(iv) \u2014O\u2014C1-10 alkyl,
(v) \u2014C3-8 cycloalkyl,
(vi) \u2014C1-10 alkyl,
(vi) \u2014C6-10 aryl, or
(4) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl,
pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl,
thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl,
wherein said heteroaryl is unsubstituted or substituted with one or more
(i) halo,
(ii) \u2014OH,
(iii) \u2014CN,
(iv) \u2014O\u2014C1-10 alkyl,
(v) \u2014C3-8 cycloalkyl,
(vi) \u2014C1-10 alkyl,
(vii) \u2014C(\u2550O)\u2014O\u2014C1-10 alkyl,
(viii) \u2014C(\u2550O)\u2014OH, and
(ix)=\u2014C(\u2550O)\u2014NRcRd,
(x) \u2014NRcRd, wherein Rc and Rd are selected from the group consisting of
\u2003(A) hydrogen, and
\u2003(B) \u2014C1-10 alkyl;
(5) hydrogen;
(6) \u2014CF3; and
(7) \u2014O\u2014SO2\u2014R9;
R3 is
wherein Rx is selected from the group consisting of
(a) hydrogen,
(b) \u2014C1-6 alkyl,
(c) \u2014C0-3 alkylene-C3-8 cycloalkyl,
(d) \u2014C0-3alkylene-C6-10 aryl
and said Rx alkyl, alkylene, cycloalkyl and aryl groups are unsubstituted or substituted with one or more
(i) halo,
(ii) \u2014C1-10 alkyl,
(iii) \u2014OH,
(iv) \u2014CN, or
\u2003and if the dotted line leading to Ry is absent, then Ry is selected from the group consisting of
(a) hydrogen,
(b) \u2014C1-10 alkyl,
(c) \u2014C2-10 alkenyl,
(d) \u2014C2-10 alkynyl,
(e) \u2014C3-8 cycloalkyl,
(f) \u2014C0-6 alkylene-C6-10 aryl, or
(g) \u2014C0-6 alkylene-heteroaryl, wherein said heteroaryl is selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl,
and said Ry alkyl, alkylene, alkenyl, alkynyl, cycloalkyl and heteroaryl groups are unsubstituted with one or more
(i) halo,
(ii) \u2014C1-10 alkyl,
(iii) \u2014OH,
(iv) \u2014CN, or
(v) \u2014O\u2014C1-10 alkyl,
\u2003and Ry\u2032 is selected from the group consisting of
(a) hydrogen, and
(b) \u2014CH3,
\u2003and if the dotted line leading to Ry represents a bond, then Ry\u2032 is absent and Ry is selected from the group consisting of
(a) \u2550CH\u2014C1-10 alkyl,
(b) \u2550CH\u2014C0-6 alkylene-C6-10 aryl, or
(c) \u2550CH2
wherein said alkyl, alkylene, cycloalkyl, aryl or heteroaryl Ry groups are unsubstituted or substituted with one or more
(i) halo,
(ii) \u2014C1-10 alkyl,
(iii) \u2014OH,
(iv) \u2014CN, or
(v) \u2014O\u2014C1-10 alkyl, or
(vi) \u2014C3-8 cycloalkyl;
\u2003Q3 is \u2014CH2\u2014;
R4 is \u2014C(\u2550O)\u2014O\u2014CH2;
R7 and R8 are selected from the group consisting of
(1) \u2014C1-10 alkyl, and
(2) \u2014C0-3 alkyene-C6-10 aryl,
wherein said alkyl, alkylene and aryl is unsubstituted or substituted with one or more
(a) halo,
(b) \u2014C1-10 alkyl,
(c) \u2014OH,
(d) \u2014CN,
(e) \u2014O\u2014C1-10 alkyl, or
(f) \u2014C3-8 cycloalkyl;
R9 is selected from the group consisting of
(1) \u2014C1-10 alkyl, and
(2) \u2014C0-3 alkylene-C6-10 aryl,
wherein said alkyl, alkylene and aryl is unsubstituted or substituted with one or more
(a) halo,
(b) \u2014C1-10 alkyl,
(c) \u2014OH,
(d) \u2014CN,
(e) \u2014O\u2014C1-10 alkyl, or
(f) \u2014C3-8 cycloalkyl, or
R9 is NR7R8;
m is 1;
n is 0;
p is 1, 2, 3, 4 or 5;
q is 2, 3, 4 or 5; and
r is 0.
2. A compound of claim 1 wherein X and Y are both hydrogen.
3. A compound of claim 1 wherein the dotted line leading to Ry is absent and Ry is selected from the group consisting of
(a) \u2014C1-10 alkyl,
(b) \u2014C2-10 alkenyl,
(c) \u2014C2-10 alkynyl,
(d) \u2014C3-8 cycloalkyl,
(e) \u2014C0-6 alkylene-C6-10 aryl, or
(f) \u2014C0-6 alkylene-heteroaryl, wherein said heteroaryl is selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl,
wherein said alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, aryl or heteroaryl are unsubstituted or substituted with one or more
(i) halo,
(ii) \u2014C1-10 alkyl,
(iii) \u2014OH,
(iv) \u2014CN,
(v) \u2014O\u2014C1-10 alkyl, or
(vi) \u2014C3-8 cycloalkyl,
and Ry\u2032 is hydrogen.
4. A compound of claim 1 wherein Rx is hydrogen.
5. A compound of claim 1 wherein A is selected from the group consisting of
(1) hydrogen, and
(2) \u2014C1-10 alkyl,
wherein said alkyl is unsubstituted or substituted with one or more
(a) halo,
(b) \u2014C3-8 cycloalkyl,
(c) \u2014CN
(e) \u2014C6-10 aryl, or
(f) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl.
6. A compound of claim 1 wherein R2 is (R5\u2014SO2)N(R6)\u2014, wherein R5 is \u2014C1-6 alkyl, wherein said alkyl is unsubstituted or substituted with one or more
(i) halo,
(ii) \u2014OH,
(iii) \u2014CN,
(iv) \u2014O\u2014C1-6 alkyl, or
(v) \u2014C1-6 alkyl, and
R6 is selected from the group consisting of
(a) hydrogen,
(b) \u2014C1-6 alkyl,
(c) \u2014C6-10 aryl,
wherein said alkyl and aryl is unsubstituted or substituted with one or more
(i) halo,
(ii) \u2014OH,
(iii) \u2014CN,
(iv) \u2014O\u2014C1-6 alkyl or
(v) \u2014C1-6 alkyl.
7. A compound of claim 1 wherein R2 is phenyl, unsubstituted or substituted with cyano.
8. A compound of claim 1 which is a compound of formula (II):
and pharmaceutically acceptable salts thereof, and individual enantiomers and diastereomers thereof.
9. A compound of claim 1 which is a compound of formula (III):
and pharmaceutically acceptable salts thereof, and individual enantiomers and diastereomers thereof.
10. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
What is claimed is:
1. A method of cutting CSP substrates comprising the steps of:
mounting plural CSP substrates on a single frame without overlapping them one upon the other, each CSP substrate having CSPs formed on plural rectangular regions thereof sectioned by the cutting streets arranged in a form of a lattice;
recognizing the mounting position of each of said CSP substrates on said frame and storing the mounting positions in a storage means;
securing said frame mounting said plural CSP substrates onto a chuck;
imaging the surface of each of said CSP substrates by a precision imaging means, recognizing the positions of said cutting streets of each of said CSP substrates on said frame secured onto said chuck by analyzing the obtained image, and storing the positions of said cutting streets in said storage means;
positioning said chuck, to which said frame is secured, relatively to each other with respect to said precision imaging means based on the stored mounting position of each of said CSP substrates on said frame at the time of imaging the surface of each of said CSP substrates by said precision imaging means; and
cutting each of said CSP substrates along said cutting streets by moving said chuck and a cutting means relatively to each other based on the stored position of said cutting streets of each of said CSP substrates.
2. A method of cutting CSP substrates according to claim 1, wherein said frame has an opening at a central portion thereof, a mounting tape extending across said opening is stuck onto the back surface of said frame, and said CSP substrates are each stuck onto said mounting tape so as to be positioned in said opening of said frame.
3. A method of cutting CSP substrates according to claim 2, wherein said mounting tape has plural mounting position indications for indicating the mounting position of each of said CSP substrates, and the mounting position of each of said CSP substrates on said frame is recognized by viewing by eyes said mounting position indications and is manually input to said storage means.
4. A method of cutting CSP substrates according to claim 2, wherein the whole surface of said frame that mounts plural pieces of said CSP substrates is imaged by a whole-surface imaging means, and the mounting position of each of said CSP substrates on said frame is recognized by analyzing the obtained image and is stored.
5. A method of cutting CSP substrates according to claim 1, wherein the number of said cutting streets and gaps among them in each of said CSP substrates are stored in said storage means, and said chuck and said cutting means are moved relatively to each other to cut each of said CSP substrates along said cutting streets based on the stored number of said cutting streets and the stored gaps among them in each of said CSP substrates.
6. A method of cutting CSP substrates according to claim 5, wherein the number of said cutting streets and the gaps among them in each of said CSP substrates are stored in said storage means by being manually input.
7. A method of cutting CSP substrates according to claim 1, wherein said frame and a pick-up means are positioned relatively to each other based on the stored positions of the cutting streets of said CSP substrates, and plural CSPs that have been cut are individually picked up from said frame by said pick-up means.